Company / Revenue
Celldex Therapeutics, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.5M
FY2025
5-year range
$1.5M / $7.0M
FY2021-FY2025
Trend
-78.0%
vs FY2024
Sector context
#154 of 155
Health Care
What the data says
Among 155 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 1% for revenue. Revenue has fluctuated over the past 10 years, ranging from $2M in FY2017 to $7M in FY2020.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -26.9%.
Declined from $7M to $2M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -13.1%
- 5-Year CAGR
- -26.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 155This company $1.5M Sector average $19.1B
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -26.9%, indicating a declining trend.
- In FY2025, revenue decreased 78.0% year-over-year.
- Ranks #154 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.5M | -78.0% |
| FY2024 | $7.0M | +2.0% |
| FY2023 | $6.9M | +192.0% |
| FY2022 | $2.4M | -49.3% |
| FY2021 | $4.7M | -37.3% |
| FY2020 | $7.4M | +107.6% |
| FY2019 | $3.6M | -47.3% |
| FY2018 | $6.8M | +342.4% |
| FY2017 | $1.5M | -77.4% |
| FY2016 | $6.8M | +23.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026